

### III. Petitions

Anyone with knowledge that any of the dates as published are incorrect may submit either electronic or written comments and, under 21 CFR 60.24, ask for a redetermination (see **DATES**). Furthermore, as specified in § 60.30 (21 CFR 60.30), any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition must comply with all the requirements of § 60.30, including but not limited to: must be timely (see **DATES**), must be filed in accordance with § 10.20, must contain sufficient facts to merit an FDA investigation, and must certify that a true and complete copy of the petition has been served upon the patent applicant. (See H. Rept. 857, part 1, 98th Cong., 2d sess., pp. 41–42, 1984.) Petitions should be in the format specified in 21 CFR 10.30.

Submit petitions electronically to <https://www.regulations.gov> at Docket No. FDA–2013–S–0610. Submit written petitions (two copies are required) to the Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Dated: June 24, 2022.

**Lauren K. Roth,**

*Associate Commissioner for Policy.*

[FR Doc. 2022–14134 Filed 6–30–22; 8:45 am]

**BILLING CODE 4164–01–P**

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Advisory Council on Alzheimer's Research, Care, and Services; Meeting

**AGENCY:** Assistant Secretary for Planning and Evaluation, HHS.

**ACTION:** Notice of meeting.

**SUMMARY:** This notice announces the public meeting of the Advisory Council on Alzheimer's Research, Care, and Services (Advisory Council). The Advisory Council provides advice on how to prevent or reduce the burden of Alzheimer's disease and related dementias (ADRD) on people with the disease and their caregivers. During the July 25, 2022 meeting the Advisory Council will hear updates from federal workgroups on efforts undertaken in the last quarter and an overview of the National Institutes of Health budget for ADRD research. The research, clinical care, long-term services and supports, and risk reduction subcommittees will

present recommendations and the Council will vote on adopting them.

**DATES:** The meeting will be held on July 25, 2022 from 9:30 a.m. to 4:00 p.m. EST.

**ADDRESSES:** The meeting will be a hybrid meeting that allows both in-person and virtual participation. The meeting will be held in Room 800 of the Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. It will also stream live at [www.hhs.gov/live](http://www.hhs.gov/live).

**Comments:** Time is allocated on the agenda to hear public comments from 3:30 p.m. to 4:00 p.m. The time for oral comments will be limited to two (2) minutes per individual. In order to provide a public comment, please register by emailing your name to [napa@hhs.gov](mailto:napa@hhs.gov) by Tuesday, July 19. Registered commenters may provide their comments either in-person or virtually. On Friday, July 22, registered commenters attending virtually will receive both a dial-in number and a link to join the meeting virtually; individuals will have the choice to either join virtually via the link, or to call in only by using the dial-in number. Note: There may be a 30–45 second delay in the livestream video presentation of the conference. For this reason, if you have pre-registered to submit a public comment, it is important to connect to the meeting by 3:15 p.m. to ensure that you do not miss your name and allotted time when called. If you miss your name and allotted time to speak, you may not be able to make your public comment. All participant audio lines will be muted for the duration of the meeting and only unmuted by the Host at the time of the participant's public comment. Should you have questions during the session email [napa@hhs.gov](mailto:napa@hhs.gov) and someone will respond to your message as quickly as possible.

In order to ensure accuracy, please submit a written copy of oral comments for the record by emailing [napa@hhs.gov](mailto:napa@hhs.gov) by Tuesday, July 26. These comments will be shared on the website and reflected in the meeting minutes.

In lieu of oral comments, formal written comments may be submitted for the record by Tuesday, July 26 to Helen Lamont, Ph.D., OASPE, 200 Independence Avenue SW, Room 424E, Washington, DC 20201. Comments may also be sent to [napa@hhs.gov](mailto:napa@hhs.gov). Those submitting written comments should identify themselves and any relevant organizational affiliations.

**FOR FURTHER INFORMATION CONTACT:** Helen Lamont, 202–260–6075, [helen.lamont@hhs.gov](mailto:helen.lamont@hhs.gov). Note: The

meeting will be available to the public live at [www.hhs.gov/live](http://www.hhs.gov/live).

**SUPPLEMENTARY INFORMATION:** Notice of these meetings is given under the Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and (a)(2)). Topics of the Meeting: federal updates, recommendations.

**Procedure and Agenda:** The meeting will be webcast at [www.hhs.gov/live](http://www.hhs.gov/live) and video recordings will be added to the National Alzheimer's Project Act website when available, after the meeting. This meeting is open to the public. Please allow 30 minutes to go through security and walk to the meeting room. The meeting will also be webcast at [www.hhs.gov/live](http://www.hhs.gov/live). Participants joining in person should note that seating may be limited. Those wishing to attend the meeting in person must send an email to [napa@hhs.gov](mailto:napa@hhs.gov) and put "July 25 Meeting Attendance" in the subject line by Tuesday, July 19 so that their names may be put on a list of expected attendees and forwarded to the security officers at the Department of Health and Human Services. Any interested member of the public who is a non-U.S. citizen should include this information at the time of registration to ensure that the appropriate security procedure to gain entry to the building is carried out. Although the meeting is open to the public, procedures governing security and the entrance to Federal buildings may change without notice. If you wish to make a public comment, you must note that within your email.

The Department of Health and Human Services follows the CDC COVID–19 Community Level in determining masking and social distancing guidelines. Please visit the Safer Federal Workforce web page for masking and social distancing guidelines for more information.

**Authority:** 42 U.S.C. 11225; Section 2(e)(3) of the National Alzheimer's Project Act. The panel is governed by provisions of Public Law 92–463, as amended (5 U.S.C. Appendix 2), which sets forth standards for the formation and use of advisory committees.

Dated: June 28, 2022.

**Benjamin Sommers,**

*Senior Official Performing the Duties of the Assistant Secretary for Planning and Evaluation, Deputy Assistant Secretary for Health Policy.*

[FR Doc. 2022–14146 Filed 6–30–22; 8:45 am]

**BILLING CODE 4150–05–P**